European Biotechnology - Latest News and Information
Technology Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
Gilead Sciences agreed to acquire German ADC specialist Tubulis for up to US$5 bn, including a US$3.15 bn cash upfront payment and up to US$1.85 bn in milestones. The deal brings Tubulis’s proprietary antibody‑drug conjugate platforms and two late‑stage assets—TUB‑040, a NaPi2b‑targeted topoisomerase‑I inhibitor in Phase Ib/II, and TUB‑030, a 5T4‑targeted ADC—into Gilead’s oncology portfolio. Tubulis will operate as an independent R&D unit within Gilead’s Munich hub, preserving its innovation engine. The acquisition aims to offset looming patent expiries and bolster Gilead’s pipeline in the fast‑growing ADC market.
Portugal’s biotech sector is shedding its niche reputation, with turnover among trade‑group members more than tripling between 2016 and 2020 and over half of firms earning the majority of revenue from exports. A multi‑node cluster model spanning Cantanhede, Porto, Braga,...
Copenhagen‑based IO Biotech, a cancer immunotherapy firm, saw its flagship melanoma vaccine Cylembio miss the primary endpoint in a Phase III trial, prompting the FDA to advise against filing for approval. The regulatory setback left the company with insufficient runway, as...
Generare, a Paris‑based tech‑bio startup, raised €20 million in Series A funding to expand its proprietary library of evolution‑derived small molecules. The company tackles the data bottleneck in AI‑driven drug discovery by decoding microbial genomes to uncover cryptic chemistry, having identified over...
